Variables | Village status | Baseline | Follow-up time | |||
---|---|---|---|---|---|---|
M0 | M3 | M6 | M9 | M12 | ||
Number of villagersa | Early MDA | 883 | 889 | 877 | 879 | 899 |
Deferred-MDA | 1036 | 1029 | 1071 | 1022 | 1022 | |
Number of Pf clinical caseb | Early MDA | 1 | 0 | 8 | 1 | 0 |
Deferred-MDA | 2 | 2 | 26 | 8 | 0 | |
Prevalence of Pf clinical case 95% CI | Early MDA | 0.0 (0.0–0.4) | 0.9 (0.4–1.7) | 0.1 (0.0–0.6) | 0 | |
Deferred-MDA | 0.2 (0.2–0.7) | 2.4 (1.6–3.5) | 0.8 (0.3–1.5) | 0 | ||
p-value | 0.192 | 0.008 | 0.035 | |||
PF exposure time (person-year) | Early MDA | N/A | 222 | 219 | 220 | 220 |
Deferred-MDA | N/A | 257 | 268 | 256 | 205 | |
Incidence of clinical Pf infection 95% CI (per 1000 person-years) | Early MDA | N/A | 0 (0–6.6) | 36 (16–72) | 4.6 (0.1–25.3) | 0 |
Deferred-MDA | N/A | 8 (0.9–28.1) | 97 (63–142) | 31 (13.5–61.6) | 0 | |
p-value | 0.288 | 0.011 | 0.037 |